Novo Nordisk’s Pill Strategy Gets a Double Boost – EU Nod and Analyst Upgrade – Yet the Growth S
Novo Nordisk shares have recouped more than 40% from their early-March low, but the stock still sits nearly…
Novo Nordisk’s Oral Wegovy Wins EU Nod: Can the Pill’s US Success Scale Across 27 Markets?
For millions of Europeans who have shunned weight-loss injections, the arrival of a daily pill could change the…
Novo Nordisk’s Oral Wegovy Nod Lifts Shares, but the Valuation Debate Rages On
Novo Nordisk added another chapter to its recovery story on Wednesday, when European regulators approved the first oral…
Novo Nordisk’s Wegovy Broadens Its Reach: UK MASH Nod, Medicare Push, and a Billion-Dollar Parent
Novo Nordisk’s bestselling GLP-1 drug is no longer tethered solely to obesity. The Danish pharma giant has locked…
Novo Nordisk’s 5.27 Billion Kroner Buyback and UK Pill Nod Trump Cyber Setback
Novo Nordisk is deploying its balance sheet to send a message of confidence even as headwinds accumulate. The…
Novo Nordisk’s Oral Wegovy Gets UK Nod as Cyber Breach Casts a Shadow
It has been a year since Novo Nordisk’s shares touched an all-time high above €70. Now trading at…